Ticker Symbol: CUR
QUEBEC CITY, Jan. 11 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a life
sciences company commercializing high-value cancer diagnostic tests and
delivering laboratory services, announced today that the Company will
release its fourth quarter and fiscal 2010 year end results on January
19, 2011, at approximately 4:30 p.m. (ET). This release will be
followed by a conference call, which will be held on January 20, 2011,
at 10:00 a.m. (ET). The conference will begin with a brief
presentation, followed by a question-and-answer period.
The event will be webcast live through DiagnoCure's website at www.diagnocure.com, through a link on the Investors page - Presentations and Conferences.
For those who wish to take part in the conference call for the Q&A
period, please dial the phone number, provide the subject «DiagnoCure
Q4 Earnings announcement» and the Conference ID: 4397687. Access phone
numbers for participants from Montreal, is 514-807-8791 and for other
participants the toll-free number is 1-800-731-5319.
For those unable to participate, a replay of the audio conference will
also be available on DiagnoCure's website as of January 21, 2011, also
through a link on the Investors page - Presentations and Conferences.
DiagnoCure (TSX: CUR) is a life sciences company commercializing
high-value cancer diagnostic tests and delivering laboratory services
that increase clinician and patient confidence in making critical
treatment decisions. DiagnoCure Oncology Laboratories, a subsidiary of
DiagnoCure, Inc., launched in 2008 the Previstage™ GCC Colorectal
Cancer Staging Test, the first GCC-based molecular test for the
management of colorectal cancer. A major study published in the
February 18, 2009, edition of the Journal of the American Medical Association demonstrated that GCC, to which DiagnoCure owns exclusive worldwide
diagnostic rights, is the strongest independent predictor of colorectal
cancer recurrence. More clinical studies are underway to confirm the
clinical utility of the Previstage™ GCC test. The Company has a
strategic alliance with Gen-Probe (NASDAQ: GPRO) for the development
and commercialization of a second-generation prostate cancer test using
PCA3, DiagnoCure's proprietary molecular marker. This test is available
through laboratories in the U.S. and in Canada using PCA3 analyte
specific reagents (ASR) from Gen-Probe, and in Europe as the CE-marked
PROGENSA® PCA3 in vitro assay. Gen-Probe completed a 500-patient clinical study aimed at
securing FDA approval for the commercialization of the PROGENSA® PCA3
test in the U.S. and filed a PMA in September 2010. For more
information, visit www.diagnocure.com.
This release contains forward‐looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual
results to differ materially from those expected. By their very nature,
forward‐looking statements are based on expectations and hypotheses and
also involve risks and uncertainties, known and unknown, many of which
are beyond DiagnoCure's control. As a result, investors are cautioned
not to place undue reliance on these forward‐looking statements. The
forward-looking statements regarding the outcome of research and
development projects, clinical studies and future revenues are based on
management expectations. In addition, the reader is referred to the
applicable general risks and uncertainties described in DiagnoCure's
most recent Annual Information Form under the heading "Risk Factors".
DiagnoCure undertakes no obligation to publicly update or revise any
forward‐looking statements contained herein unless required by the
applicable securities laws and regulations.
SOURCE DIAGNOCURE INC.
For further information: